Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.
- Registration Number
- NCT05285397
- Lead Sponsor
- General Committee of Teaching Hospitals and Institutes, Egypt
- Brief Summary
Our primary objective is to assess the effect of Liraglutide on weight loss in patients who have undergone secondary bariatric surgeries. We set out to assess if Liraglutide is a viable option to augment weight loss in said category.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- Undergone primary bariatric surgery
- Need secondary bariatric surgery due to either weight regain (regained weight to have BMI > 35) or medical associated diseases
Exclusion Criteria
- Prior use of GLP-1 agonist
- Past history of pancreatitis
- Personal or family history of medullary thyroid cancer
- Pregnancy or lactation
- Acute coronary syndrome
- Hepatic or renal dysfunction
- Active malignancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Liraglutide Liraglutide Pen Injector [Saxenda] drug starts 6 weeks post-operative until 6 months SC injection dose starting 0.6 mg/day and weekly up titrated until 3.0 mg/day
- Primary Outcome Measures
Name Time Method Percentage Excess body weight loss 6 months Percentage Total weight loss 6 months
- Secondary Outcome Measures
Name Time Method Sleep apnea 6 months Lipid profile 6 months Comorbidities 6 months Weight 6 months BMI 6 months HOMA-IR 6 months HbA1C 6 months Resolution of type 2 Diabetes Mellitus 6 months Fasting Blood Glucose (FBG) 6 months Blood pressure 6 months
Trial Locations
- Locations (1)
Madina Women's Hospital
šŖš¬Alexandria, Egypt